Skip to main content
Premium Trial:

Request an Annual Quote

Solvd Health Gets CE Mark for Opioid Use Disorder Risk Assessment Test

NEW YORK — Solvd Health said on Monday that it has received CE marking for its genetic risk assessment test for opioid use disorder.

According to the Carlsbad, California-based company, the test analyzes a cheek swab sample for 15 genetic variants that have been implicated in the brain's reward pathway and can help guide the use of oral opioids for acute pain.

"Any time prescription opioids are used to manage pain, there is a risk of addiction," Solvd CEO Keri Donaldson said in a statement. "Knowing a patient's risk prior to opioid exposure gives clinicians and patients the data they need to make more informed decisions."

Solvd said the test is currently under review by the US Food and Drug Administration, which granted it a breakthrough device designation in 2018.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more